You are here


Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors

The National Cancer Institute (NCI) seeks co-development or licensees for Dual-Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors
NIH Reference Number
Product Type
  • Dual-Specific Chimeric Antigen Receptors, CAR, CD19, CD22, Oncology, Cancer, Fry
Collaboration Opportunity
This invention is available for licensing and co-development.
Description of Technology

Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC-) independent manner to kill tumor cells expressing the target to which the scFv binds.  CAR T cells targeting the B cell antigen CD19 have resulted in remissions in 60-80% of patients with pre-B cell precursor acute lymphoblastic leukemia (BCP-ALL). However, not all patients respond, and relapses occur in 10% or more of patients who receive anti-CD19 CAR therapy for acute lymphoblastic leukemia (ALL) - primarily due to the loss of the CD19 epitope. Thus, there is a need for advanced therapeutic options to treat those patients who either relapse or are non-responders.
To overcome these current limitations, the National Cancer Institute’s Pediatric Oncology Branch (NCI POB) developed an active CD19/CD22 targeted CAR that is potent at eradicating ALL in xenograft studies (Haso et al, Blood, 2013); a Phase I clinical trial is planned. Targeting two antigens simultaneously could increase CAR potency and prevent antigen-loss escape.
The inventors are interested in co-development or licensing opportunities for this technology.

Potential Commercial Applications
  • Treatment of acute lymphoblastic leukemia (ALL), the most common form of cancer for children ages 1 to 7 years old and afflicts roughly 3000‐3500 persons annually in the US. In 2013, the US had the largest market with a market share of approximately 55% to 60% of the acute lymphocytic/lymphoblastic leukemia therapeutics market in G8 countries, followed by Germany and Italy  
  • Treatment of general hematological cancers
  • Adoptive immunotherapy
Competitive Advantages
  • Large market for immunotherapies to treat ALL, an aggressive form of leukemia that occurs in adults and children 
Development Stage

Haso W, et al. Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.  [PMID 23243285]

Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number 15/559,485 , Filed 19 Sep 2017
Therapeutic Area
Thursday, August 2, 2018